REACH (Reversing the Epidemic in Africa with Choices in HIV prevention), or MTN-034/IPM 045, is a Phase IIa study that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women, who are among the most vulnerable to HIV in sub-Saharan Africa. Specifically, REACH will evaluate how adolescent girls and young women use the monthly dapivirine vaginal ring and Truvada® as daily pre-exposure prophylaxis (PrEP) and their preferences for either or both approaches. The study will also collect much needed information on the safety of these approaches in young women. The study, which is expected to launch early 2019, will enroll approximately 300 girls and young women ages 16-21 at five trial sites in Kenya, Uganda, South Africa and Zimbabwe.
See
About the REACH Study (MTN-034)
17-October-2018
9-May-2018
Dapivirine Ring Studies in adolescent girls and young women Q&A
12-October-2017
See also
HIV prevention dapivirine vaginal ring found safe and acceptable in US adolescent girls
25-July-2017
Meeting Report: Stakeholders consultation on REACH (MTN-034)
December-2016